| Company/Division name | Ideal Health Biotechnology |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2017 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | China |
| City reshored to: | Kannapolis |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Vitamins |
| What non-domestic negative factors made offshoring less attractive? | Product liability |
| What domestic positive factors made reshoring more attractive? | Image/brand |
